

Chromium does not belong in the diabetes treatment arsenal: Current evidence and future perspectives

Gijs WD Landman, Henk JG Bilo, Sebastiaan T Houweling, Nanne Kleefstra

Gijs WD Landman, Henk JG Bilo, Sebastiaan T Houweling, Nanne Kleefstra, Diabetes Centre, Isala, 8000 GK Zwolle, The Netherlands

Henk JG Bilo, Department of Internal Medicine, University Medical Center, 9700 RB Groningen, The Netherlands

Sebastiaan T Houweling, Department of General Practice, University Medical Centre, 9700 RB Groningen, The Netherlands

Author contributions: Landman GWD and Kleefstra N Performed literature search; Landman GWD and Kleefstra N analyzed literature search results; Landman GWD, Bilo HJG, Houweling ST and Kleefstra N wrote the paper.

Correspondence to: Gijs WD Landman, MD, PhD, Diabetes Centre, Isala, P.O. box 10400, 8000 GK Zwolle, The Netherlands. g.w.d.landman@isala.nl

Telephone: +31-38-4242518 Fax: +31-38-4247694

Received: December 11, 2013 Revised: January 23, 2014

Accepted: March 13, 2014

Published online: April 15, 2014

Abstract

Chromium is considered to have positive effects on insulin sensitivity and is marketed as an adjunctive therapy for inducing glucose tolerance in cases of insulin resistance ("the glucose tolerance factor"). Case reports on patients who received prolonged parenteral nutrition indeed showed that the absence of trivalent chromium caused insulin resistance and diabetes. However, whether patients with type 2 diabetes can develop a clinically relevant chromium deficiency is unclear. This review summarizes the available evidence regarding the potential effectiveness of chromium supplementation on glycemic control (Hemoglobin A1c levels) in patients with type 2 diabetes. No studies investigating the long-term safety of chromium in humans were found. All clinical trials that have been performed had a relative short follow-up period. None of the trials investigated whether the patients had risk factors for chromium deficiency. The evidence from randomized trials in patients with

type 2 diabetes demonstrated that chromium supplementation does not effectively improve glycemic control. The meta-analyses showed that chromium supplementation did not improve fasting plasma glucose levels. Moreover, there were no clinically relevant chromium effects on body weight in individuals with or without diabetes. Future studies should focus on reliable methods to estimate chromium status to identify patients at risk for pathological alterations in their metabolism associated with chromium deficiency. Given the present data, there is no evidence that supports advising patients with type 2 diabetes to take chromium supplements.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Chromium; Type 2 diabetes mellitus; Insulin resistance; Therapy; Supplements

Core tip: In some patients who received prolonged parenteral nutrition, absence of trivalent chromium caused insulin resistance and diabetes and supplementation with trivalent chromium "cleared" this metabolic disease. The question is, whether chromium deficiency is a relevant factor in the cause of type 2 diabetes in general and whether supplementation with trivalent chromium can have beneficial effects in type 2 diabetes. Unfortunately, no reliable methods to estimate chromium status exists and according to current evidence, chromium does not improve glycemic control in patients with type 2 diabetes and patients should be advised not to take chromium supplements.

Landman GWD, Bilo HJG, Houweling ST, Kleefstra N. Chromium does not belong in the diabetes treatment arsenal: Current evidence and future perspectives. *World J Diabetes* 2014; 5(2): 160-164 Available from: URL: <http://www.wjgnet.com/1948-9358/full/v5/i2/160.htm> DOI: <http://dx.doi.org/10.4239/wjd.v5.i2.160>

INTRODUCTION

Insulin resistance is an important target for pharmacological and non-pharmacological interventions in patients with type 2 diabetes. In addition to the well-established interventions, a multitude of suggested alternative solutions outside the field of regular conventional medicine is available. One of these suggested beneficial interventions is oral supplementation with chromium. Chromium is marketed as a substance that improves insulin sensitivity (being as part of the “Glucose Tolerance Factor” molecule), weight loss and improving glycemic control in patients with diabetes^[1,2]. Chromium has become the second most popular dietary supplement after calcium in the United States, with sales amounting to approximately 100 million dollars annually^[1,2].

Some studies have demonstrated that chromium supplementation in chromium deficient states indeed led to beneficial effects^[3-6]. There are strong arguments supporting the hypothesis that chromium supplementation improves glycemic control in chromium deficient patients by improving insulin sensitivity^[7]. In addition, patients with diabetes are thought to have a chromium deficient status that is induced by an altered chromium metabolism^[4,8,9]. However, other studies have suggested that chromium metabolism is not altered in type 2 diabetes^[10]. Unfortunately, cut-off points for chromium levels correlating with relevant changes in glucose metabolism and insulin resistance are lacking. There is no clinically defined chromium deficiency state, nor is there a validated method for estimating the total body chromium status^[11-13]. A reliable assessment of the chromium status in biological tissues and fluids is difficult due to extremely low chromium levels^[12]. Although some studies have demonstrated successful chromium level determination in hair, sweat, and blood, there is still no exact method for defining chromium deficiency^[8]. In this theoretical framework the “diabetic state” is linked to chromium deficiency and chromium supplementation would amend glycemic control by improving insulin sensitivity. This review discusses chromium physiology and summarizes the current evidence that chromium supplementation improves glycemic control in patients with type 2 diabetes.

Several case reports demonstrated beneficial effects of chromium supplementation in patients requiring total parenteral nutrition for prolonged periods^[3,5-7,14,15]. One case report, published in 1977, discussed a 40-year-old woman who had undergone a total enterectomy after mesenteric thrombosis and became dependent on total parenteral nutrition^[14]. After three years, she started losing weight and developed diabetes mellitus. She was young, had a low body weight, and required 50 IE of insulin daily to reach a near-normoglycemic state. Chromium deficiency was considered as a possible cause. The chromium concentration in her serum and hair was measured and found to be low [154 ng/g (N > 500 ng/g) and 0.55 ng/g (N = 4.9-9.5 ng/g), respectively]. She was treated intravenously with 250 micrograms of chromium chloride daily for two weeks. This treatment decreased

the amount of insulin needed, and after four months of chromium supplementation, she remained normoglycemic without insulin. After this and several other case reports^[3,9,14], chromium was added to parenteral nutrition as a standard ingredient^[6]. Nevertheless, the extent of chromium supplementation necessary during total parenteral nutrition is still debated^[16,17].

CHROMIUM PHYSIOLOGY

The two most common forms of chromium are the trivalent (3+) and the hexavalent (6+) forms. Chromium 6+ is not present in nature and is toxic. The chromium found in food and in dietary supplements is the trivalent form. Whole grain products, such as whole grain bread, vegetables, nuts, and some spices contain low concentrations of trivalent chromium. Chromium supplements are available as chromium chloride, chromium nicotinate, chromium picolinate, high-chromium yeast, and chromium citrate. Chromium chloride appears to have a poor bioavailability, although there is limited data on chromium absorption in humans^[12,15,18].

The role of trivalent chromium in glucose metabolism has been known since the 1950s^[15]. Chromium can alter insulin sensitivity at the cellular level. The oligopeptide Apo-Low-Molecular-Weight-Chromium binding peptide (also known as Apo-chromoduline) plays an important role in potentiating the insulin response in insulin sensitive cells^[18,19]. The Apo-chromoduline is loaded intracellularly with a maximum of four chromium ions. Chromium-loaded Apo-chromoduline is called Holo-chromoduline. The Holo-chromoduline molecule binds to the insulin receptor and potentiates the insulin response by activating the receptor. The degree of insulin receptor activation depends on the number of chromium ions bound to this peptide, with a minimum of 0 and a maximum of 4 ions. This chromium binding may lead to an 8-fold difference in insulin receptor activation (when 4 ions are bound compared to 0). Experiments using rat adipocyte cells with equal serum insulin concentrations confirmed that insulin receptor activation is eight times stronger in the presence of chromium than in the absence of chromium^[18].

ADVERSE EFFECTS OF CHROMIUM

Several cell culture and animal studies using supraphysiological chromium doses yielded results suggesting that chromium may increase DNA damage^[20-23]. Chromium is not unique in this respect; a number of other nutrients such as vitamins A and D, nicotinic acid, and selenium have also been implicated in causing toxicity when taken in excess^[24]. Clinical trials of oral chromium supplementation did not demonstrate toxicity in patients on parenteral nutrition^[24,25]. We could not find long-term chromium safety studies. The DNA damage identified in cases of supraphysiological trivalent chromium concentrations did not translate into potentially carcinogenic effects when a more physiological dose of oral trivalent chromium was

used in humans^[24,26].

CLINICAL EVIDENCE FOR CHROMIUM USE

In 1997, the intervention trial by Anderson *et al.*^[27] was one of the first chromium-intervention studies in patients with type 2 diabetes. In this randomized controlled trial, chromium picolinate supplements or placebo were administered to 180 Chinese patients with type 2 diabetes. The patients were randomized into three groups: placebo, 200 mg chromium, and 1000 mg of chromium daily. After four months, the hemoglobin A1c (HbA1c) levels in the placebo group were unchanged (8.5%), while they decreased significantly in the 200 mg group, from 8.5% to 7.5%, and decreased in the 1000 mg group, from 8.5% to 6.6%.

In 2007, Balk *et al.*^[28] performed a systematic review of randomized controlled trials investigating chromium supplementation in patients with type 2 diabetes. At that time, 14 studies with 18 different chromium-based interventions had been performed using HbA1c levels as an endpoint. In 11 out of these 14 trials, there was no significant effect of chromium supplementation. The review by Balk *et al.*^[28] concluded that, due to the poor quality and heterogeneity of the data, additional studies addressing these limitations were needed before definitive claims could be made about the effect of chromium supplementation^[28]. Nevertheless, the meta-analysis by Balk *et al.*^[28] reported an overall significant effect of chromium supplementation on HbA1c levels (-0.6%; 95%CI: -0.9% to -0.2%). This -0.6% mean benefit was largely due to the inclusion of the data reported by Anderson *et al.*^[27]. When the Anderson study was excluded, the effect of chromium on HbA1c levels was -0.3% (95%CI: -0.5% to -0.1%; NS)^[28]. It should be noted however, that the Anderson study was inadequately blinded with concerns for detection bias and selection bias, and should be considered to be of poor-methodological quality^[27,28].

Significant effects in the meta-analysis were only found in studies with poor methodological quality or in studies sponsored by chromium supplement producing companies. In addition, the effects of chromium supplementation were shown to be absent or non-relevant after stratifying the studies according to methodological quality, sponsor involvement, and a western *vs* non-western study location^[6,29].

After the review written by Balk *et al.*^[28], a second Dutch double blind trial was performed in 2008 that studied the effects of chromium on HbA1c levels in patients with type 2 diabetes^[29]. After 6 mo, the effect of chromium supplementation compared to placebo on HbA1c levels was 0.24% (95%CI: -0.06% to 0.54%). HbA1c levels were lower in the placebo group compared with the chromium group. All of the trials that have been performed had a relatively short follow-up period. No studies have been performed with sufficient follow-up and the ability to reliably investigate cardiovascular and/or microvascular end-points. All studies used surrogate

end-points. None of the trials investigated whether patients had risk factors for chromium deficiency.

Although this review focuses on the most relevant method of estimating glycemic control (HbA1c levels)^[30-32], several studies investigated the effect of chromium on other markers of glycemic control^[11,13,33-35]. Meta-analyses showed that chromium supplementation did not improve fasting plasma glucose levels^[33,36] and had no clinically relevant effect on body weight in individuals with or without diabetes^[37-39].

DISCUSSION

Chromium plays a role in insulin physiology, and severe chromium deficiency can lead to insulin resistance. Chromium supplementation may be beneficial in rare cases of prolonged total parental nutrition when standard chromium supplementation is lacking^[6]. Despite the lack of sufficient evidence that chromium supplementation improves glycemic control^[28,29], chromium is still widely marketed as an effective supplement for improving glycemic control in patients with type 2 diabetes.

Do we need to worry that a low chromium status contributes to hyperglycemia in our patients?

For the average patient with type 2 diabetes, the answer is no. Trivalent chromium is sufficiently available in food, and the occurrence of severe chromium deficiency is highly unlikely. The sparse evidence that chromium supplementation might have effects on glycemic control in a broader population is derived from studies with important methodological flaws^[27,28]. Well-performed trials and meta-analyses consistently show that there is no evidence for consistent beneficial effects on glycemic control (as assessed by HbA1c levels) that support prescribing chromium supplements to patients with type 2 diabetes^[6,40]. Furthermore, the long-term safety of chromium supplementation has not been established.

Is all hope lost for chromium supplementation in patients with type 2 diabetes?

An important concern when interpreting the data from studies investigating chromium effects is the lack of a validated and precise estimate of chromium status. There is no reliable method for assessing the body's chromium status, and there is no information on the bioavailability of the different forms of chromium^[41]. Performing randomized trials in patients with type 2 diabetes will become interesting only when we can properly assess the chromium status in patients at risk for chromium deficiency and when clinically relevant end points are defined.

Recommendations

Future research on chromium should focus on establishing a reliable method for assessing the body's chromium status. The bioavailability of different forms of chromium in Western and non-Western patients should be investigated in order to define a potential effective dose

and to identify patients at risk for chromium deficiency. New randomized trials should only be considered in type 2 diabetes patients with an established chromium deficiency. The long-term safety of chromium supplementation should be investigated in large population studies. Currently, chromium supplementation in patients with type 2 diabetes should not be recommended.

REFERENCES

- National Toxicology Program.** Executive Summary Chromium Picolinate. Available from: URL: <http://ntp.niehs.nih.gov/?objectid=6F5E980E-F1F6-975E-7CA23E823F2CB959>
- Nielsen F.** Controversial chromium: does the superstar mineral of the mountebanks receive appropriate attention from clinicians and nutritionists? *Nutr Today* 1996; **31**: 226-233 [DOI: 10.1097/00017285-199611000-00002]
- Brown RO, Forloines-Lynn S, Cross RE, Heizer WD.** Chromium deficiency after long-term total parenteral nutrition. *Dig Dis Sci* 1986; **31**: 661-664 [PMID: 3086063 DOI: 10.1007/BF01318699]
- Kozlovsky AS, Moser PB, Reiser S, Anderson RA.** Effects of diets high in simple sugars on urinary chromium losses. *Metabolism* 1986; **35**: 515-518 [PMID: 3713513 DOI: 10.1016/026-0495(86)90007-7]
- Case records of the Massachusetts General Hospital.** Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-1990. A 21-year-old man with progressive gastrointestinal stasis, hepatomegaly, and a neurologic disorder. *N Engl J Med* 1990; **322**: 829-841 [PMID: 2155390 DOI: 10.1056/NEJM199003223221208]
- Anderson RA.** Chromium and parenteral nutrition. *Nutrition* 1995; **11**: 83-86 [PMID: 7749258]
- Freund H, Atamian S, Fischer JE.** Chromium deficiency during total parenteral nutrition. *JAMA* 1979; **241**: 496-498 [PMID: 104057 DOI: 10.1001/jama.1979.03290310036012]
- Davies S, McLaren Howard J, Hunnisett A, Howard M.** Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients--implications for the prevention of cardiovascular disease and type II diabetes mellitus. *Metabolism* 1997; **46**: 469-473 [PMID: 9160809 DOI: 10.1016/S0026-0495(97)90179-7]
- Anderson RA, Kozlovsky AS.** Chromium intake, absorption and excretion of subjects consuming self-selected diets. *Am J Clin Nutr* 1985; **41**: 1177-1183 [PMID: 4003325]
- Zima T, Mestek O, Tesar V, Tesarova P, Nemecek K, Zak A, Zeman M.** Chromium levels in patients with internal diseases. *Biochem Mol Biol Int* 1998; **46**: 365-374 [PMID: 9801804]
- Rabinowitz MB, Gonick HC, Levin SR, Davidson MB.** Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. *Diabetes Care* 1983; **6**: 319-327 [PMID: 6352208 DOI: 10.2337/diacare.6.4.319]
- Cefalu WT, Hu FB.** Role of chromium in human health and in diabetes. *Diabetes Care* 2004; **27**: 2741-2751 [PMID: 15505017 DOI: 10.2337/diacare.27.11.2741]
- Trumbo PR, Ellwood KC.** Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration. *Nutr Rev* 2006; **64**: 357-363 [PMID: 16958312 DOI: 10.1111/j.1753-4887.2006.tb00220.x]
- Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A.** Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. *Am J Clin Nutr* 1977; **30**: 531-538 [PMID: 192066]
- SCHWARZ K, MERTZ W.** Chromium(III) and the glucose tolerance factor. *Arch Biochem Biophys* 1959; **85**: 292-295 [PMID: 14444068 DOI: 10.1016/0003-9861(59)90479-5]
- Moukarzel A.** Chromium in parenteral nutrition: too little or too much? *Gastroenterology* 2009; **137**: S18-S28 [PMID: 19874946 DOI: 10.1053/j.gastro.2009.08.048]
- Moukarzel AA, Song MK, Buchman AL, Vargas J, Guss W, McDiarmid S, Reyen L, Ament ME.** Excessive chromium intake in children receiving total parenteral nutrition. *Lancet* 1992; **339**: 385-388 [PMID: 1346659 DOI: 10.1016/0140-6736(92)90078-H]
- Davis CM, Vincent JB.** Chromium oligopeptide activates insulin receptor tyrosine kinase activity. *Biochemistry* 1997; **36**: 4382-4385 [PMID: 9109644]
- Sun Y, Ramirez J, Woski SA, Vincent JB.** The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr. *J Biol Inorg Chem* 2000; **5**: 129-136 [PMID: 10766445]
- Cupo DY, Wetterhahn KE.** Binding of chromium to chromatin and DNA from liver and kidney of rats treated with sodium dichromate and chromium(III) chloride in vivo. *Cancer Res* 1985; **45**: 1146-1151 [PMID: 2578874]
- Stearns DM, Belbruno JJ, Wetterhahn KE.** A prediction of chromium(III) accumulation in humans from chromium dietary supplements. *FASEB J* 1995; **9**: 1650-1657 [PMID: 8529846]
- Wada O, Wu GY, Yamamoto A, Manabe S, Ono T.** Purification and chromium-excretory function of low-molecular-weight, chromium-binding substances from dog liver. *Environ Res* 1983; **32**: 228-239 [PMID: 6617615 DOI: 10.1016/013-9351(83)90210-4]
- Yamamoto A, Wada O, Ono T.** Distribution and chromium-binding capacity of a low-molecular-weight, chromium-binding substance in mice. *J Inorg Biochem* 1984; **22**: 91-102 [PMID: 6502162 DOI: 10.1016/0162-0134(84)80018-5]
- Jeejeebhoy KN.** The role of chromium in nutrition and therapeutics and as a potential toxin. *Nutr Rev* 1999; **57**: 329-335 [PMID: 10628183 DOI: 10.1111/j.1753-4887.1999.tb06909.x]
- Dahlstrom KA, Ament ME, Medhin MG, Meurling S.** Serum trace elements in children receiving long-term parenteral nutrition. *J Pediatr* 1986; **109**: 625-630 [PMID: 3093658 DOI: 10.1016/S0022-3476(86)80225-6]
- De Flora S.** Threshold mechanisms and site specificity in chromium(VI) carcinogenesis. *Carcinogenesis* 2000; **21**: 533-541 [PMID: 10753182 DOI: 10.1093/carcin/21.4.533]
- Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J.** Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. *Diabetes* 1997; **46**: 1786-1791 [PMID: 9356027 DOI: 10.2337/diab.46.11.1786]
- Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG.** Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. *Diabetes Care* 2007; **30**: 2154-2163 [PMID: 17519436 DOI: 10.2337/dc06-0996]
- Kleefstra N, Houweling ST, Bakker SJ, Verhoeven S, Gans RO, Meyboom-de Jong B, Bilo HJ.** Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. *Diabetes Care* 2007; **30**: 1092-1096 [PMID: 17303791 DOI: 10.2337/dc06-2192]
- The Diabetes Control and Complications Trial Research Group.** The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; **329**: 977-986 [PMID: 8366922 DOI: 10.1056/NEJM199309303291401]
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 837-853 [PMID: 9742976 DOI: 10.1016/

- S0140-6736(98)07019-6]
- 32 **White NH**, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. *Diabetes* 2010; **59**: 1244-1253 [PMID: 20150283 DOI: 10.2337/db09-1216]
- 33 **Guimarães MM**, Martins Silva Carvalho AC, Silva MS. Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. *J Am Coll Nutr* 2013; **32**: 243-250 [PMID: 24024769 DOI: 10.1080/07315724.2013.816598]
- 34 **Racek J**, Sindberg CD, Moesgaard S, Mainz J, Fabry J, Müller L, Ráková K. Effect of chromium-enriched yeast on fasting plasma glucose, glycated haemoglobin and serum lipid levels in patients with type 2 diabetes mellitus treated with insulin. *Biol Trace Elem Res* 2013; **155**: 1-4 [PMID: 23921483 DOI: 10.1007/s12011-013-9758-9]
- 35 **Sarmiento RA**, Silva FM, Sbruzzi G, Schaan BD, Almeida JC. Antioxidant micronutrients and cardiovascular risk in patients with diabetes: a systematic review. *Arq Bras Cardiol* 2013; **101**: 240-248 [PMID: 23877741]
- 36 **Bailey CH**. Improved meta-analytic methods show no effect of chromium supplements on fasting glucose. *Biol Trace Elem Res* 2014; **157**: 1-8 [PMID: 24293356]
- 37 **Althuis MD**, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. *Am J Clin Nutr* 2002; **76**: 148-155 [PMID: 12081828]
- 38 **Pittler MH**, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. *Int J Obes Relat Metab Disord* 2003; **27**: 522-529 [PMID: 12664086]
- 39 **CONSORT**. Baseline data. Available from: URL: http://www.consort-statement.org/consort-statement/13-19---results/item15_baseline-data/
- 40 **Kleefstra N**, Houweling ST, Bilo HJ. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. *Diabetes Care* 2007; **30**: e102; author reply e103 [PMID: 17726181]
- 41 **Love ST**, Di Bona KR, Sinha SH, McAdory D, Skinner BR, Rasco JF, Vincent JB. Urinary chromium excretion in response to an insulin challenge is not a biomarker for chromium status. *Biol Trace Elem Res* 2013; **152**: 57-65 [PMID: 23296902 DOI: 10.1007/s12011-012-9594-3]

P- Reviewers: Koya D, Zhao J **S- Editor:** Ma YJ
L- Editor: A **E- Editor:** Wu HL





百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,

315-321 Lockhart Road, Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

